Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Emmaus Medical

Request full access

Emmaus Life Sciences, Inc.: Clinical trial for sickle cell anemia

Torrance, United StatesFounded 2000Biotech & Life Sciences

About Emmaus Medical

Emmaus Life Sciences is a commercial-stage biopharmaceutical firm focused on treatments for rare and orphan diseases. The company was founded in 2003 by Dr. Yutaka Niihara, MD, MPH, to commercially develop a treatment for sickle cell disease (SCD) that he began researching in 1992 at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center. Dr. Niihara, the company's Chairman and CEO, was driven to find a practical therapy to alleviate the intense pain he witnessed in his SCD patients early in his career. His research, spanning over two decades, led to the development of the company's principal product.

The company's core business revolves around the marketing and sale of its lead product, Endari®, a pharmaceutical-grade L-glutamine oral powder. This prescription therapy is indicated to reduce the acute complications of sickle cell disease, such as severe pain crises, in adult and pediatric patients aged five years and older. The U.S. Food and Drug Administration (FDA) granted Endari approval in July 2017, making it the first new treatment for SCD in nearly 20 years and the first ever approved for children with the condition. The company's revenue is generated from the sale of Endari®, which is available through specialty pharmacies with a prescription. Emmaus is actively seeking marketing approval in other global regions with significant SCD populations, and has already gained authorization in several countries in the Middle East.

Endari® works by increasing the amount of the amino acid glutamine in the blood. While the exact mechanism is not fully understood, it is believed to help restore the balance of certain molecules (NAD+/NADH) in red blood cells, which may protect them from oxidative damage. This action helps red blood cells remain flexible, improving blood flow and reducing the frequency of painful crises and hospitalizations. The product is an oral powder that is mixed with a beverage or soft food and taken twice daily. Clinical studies have demonstrated its effectiveness in reducing the frequency of sickle cell crises and hospitalizations, and it can be used either as a standalone therapy or in conjunction with hydroxyurea.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 2019

Emmaus Medical in the Torrance ecosystem

Live from Dealroom

The Emmaus Medical office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later3 investors entered at this stage

  • Agility Capital
  • GPB Capital Holdings
  • Lincoln Park Capital Fund
Team profiled 5 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
5 countries with
team presence
🇺🇸 United States64%
🇦🇪 United Arab Emirates20%
🇸🇦 Saudi Arabia8%
🇰🇼 Kuwait4%
🇯🇵 Japan4%
5 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Emmaus Medical on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Emmaus Medical on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.